Skip to main content

Table 1 Demographic characteristics of EINSTEIN DVT and EINSTEIN PE patients combined

From: Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

  Rivaroxaban n = 4150 Enoxaparin/VKA n = 4131
Age, median (Q1–Q3), y 58.0 (45.0–71.0) 59.0 (45.0–70.0)
Female sex, n (%) 1848 (44.5) 1917 (46.4)
Weight, median (Q1–Q3), kg 80.0 (70.0–93.0) 80.0 (70.0–93.0)
Creatinine clearance   
 ≥80 ml/min, n (%) 2772 (66.8) 2797 (67.7)
   Age, median (Q1–Q3), y 50.0 (39.0–61.0) 51.0 (40.0–61.0)
   Female sex, n (%) 1113 (40.2) 1140 (40.8)
   Weight, median (Q1–Q3), kg 85.0 (74.0–98.0) 85.0 (75.0–98.0)
 50–79 ml/min, n (%) 1036 (25.0) 1001 (24.2)
   Age, median (Q1–Q3), y 71.0 (64.0–77.0) 71.0 (65.0–77.0)
   Female sex, n (%) 520 (50.2) 553 (55.2)
   Weight, median (Q1–Q3), kg 74.8 (65.0–82.0) 74.0 (65.0–82.0)
 30–49 ml/min, n (%) 323 (7.8) 313 (7.6)
   Age, median (Q1–Q3), y 80.0 (75.0–84.0) 79.0 (75.0–83.0)
   Female sex, n (%) 209 (64.7) 210 (67.1)
   Weight, median (Q1–Q3), kg 67.0 (59.0–75.1) 67.8 (59.0–75.0)
 <30 ml/min, n (%) 10 (0.2) 11 (0.3)
   Age, median (Q1–Q3), y 80.5 (73.0–86.0) 79.0 (77.0–86.0)
   Female sex, n (%) 5 (50.0) 11 (100.0)
   Weight, median (Q1–Q3), kg 60.0 (50.0–68.0) 70.0 (48.0–75.0)
 Missing, n (%) 9 (0.2) 9 (0.2)
Risk factors for VTE   
 Unprovoked VTE, n (%) 2003 (48.3) 2048 (49.6)
 Previous VTE, n (%) 791 (19.1) 819 (19.8)
 Active cancer, n (%) 232 (5.6) 198 (4.8)
  1. Q, Quartile; VKA, Vitamin K antagonist; VTE, Venous thromboembolism.